{"denoms":[{"counts":[{"groupId":"BG000","value":"51"}],"units":"Participants"}],"groups":[{"description":"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.\n\nTRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.\n\nPOST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11.\n\ncyclophosphamide: Given IV\n\nbusulfan: Given IV\n\ntacrolimus: Given IV or PO\n\nmethotrexate: Given IV\n\ncytogenetic analysis: Correlative studies\n\nflow cytometry: Correlative studies\n\npharmacological study: Correlative studies\n\npharmacogenomic studies: Correlative studies\n\nperipheral blood stem cell transplantation: Undergo PBPC transplantation\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic transplantation","id":"BG000","title":"Treatment (Cyclophosphamide, Busulfan, Transplant)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"30","upperLimit":"65","value":"55"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"30"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}